Key result
Volanesorsen effectively reduces elevated triglyceride levels in patients with familial chylomicronemia syndrome by targeting apo C-III, though thrombocytopenia may limit its use.
Why the study?
Patients with familial chylomicronemia syndrome lack lipolytic capacity and are resistant to standard medications.
Does volanesorsen reduce elevated triglyceride levels in patients with familial chylomicronemia syndrome?
Does volanesorsen reduce elevated triglyceride levels in patients with familial chylomicronemia syndrome?
Volanesorsen is highly effective at reducing triglycerides in familial chylomicronemia syndrome by targeting apo C-III, though its clinical utility may be limited by thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
FCS requires lifelong very low-fat diet to avert pancreatitis; leaves open optimal sequencing of emerging apoC-III therapies.
Lazarte et al. (2021) conducted a review in Familial chylomicronemia syndrome (FCS). Volanesorsen was evaluated on Triglyceride levels. Volanesorsen effectively reduces elevated triglyceride levels in patients with familial chylomicronemia syndrome by targeting apo C-III, though thrombocytopenia may limit its use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: